US Patent 6,974,578: Claims, Expiration, Litigation Risk, and Botulinum Toxin Patent Landscape

US Patent 6,974,578 covered the use of botulinum toxin to reduce sweat secretion, including treatment of cholinergically influenced sweat glands and administration by local injection. The patent issued on December 13, 2005, and its enforceable term has expired. Its commercial importance was greatest before and during the launch of Botox for severe primary axillary hyperhidrosis. The claims were commercially broad but exposed to substantial validity pressure because they combined a known pharmacologic mechanism, botulinum toxin, with a specific clinical indication, hyperhidrosis.

What does US Patent 6,974,578 claim?

The patent claims methods for reducing sweat secretion by administering botulinum toxin. The independent claim groups are:

Claim group	Core limitation	Practical scope
Claims 1-4	Administering botulinum toxin to reduce sweat secretion	Broad method-of-treatment coverage
Claims 5-9	Treating a sweat gland by administering toxin to the gland or local area	Local administration and gland-directed treatment
Claim 10	Injecting botulinum toxin type A into an excessively secreting, cholinergically influenced sweat gland or local area in a human	Narrowest commercially relevant claim
Claims 11-12	Botulinum toxin types A, B, C, D, E, F or G	Multi-serotype coverage

The central commercial concept is the treatment of hyperhidrosis with locally injected botulinum toxin. Claim 4 is the clearest claim for conventional Botox treatment of primary focal hyperhidrosis because it requires:

A human patient;
Cholinergically influenced sweat secretion;
Botulinum toxin type A;
A therapeutically effective amount; and
Reduction of sweat secretion.

Claim 10 is narrower because it requires injection into an excessively secreting sweat gland or the local sweat-gland area. Claims 1 and 5 are broader but have greater potential vulnerability to claim-construction, written-description, enablement and infringement-proof challenges.

What are the key patent details for US 6,974,578?

Field	Information
Patent number	US 6,974,578 B2
Title	Treatment of hyperhidrosis with botulinum toxin
Applicant/assignee	Allergan, Inc. and related Allergan entities
Filing date	June 30, 2000
Earliest claimed priority	June 30, 1999
Issue date	December 13, 2005
Technology	Local botulinum toxin treatment of excessive sweating
Main product relevance	Botox, onabotulinumtoxinA
Patent category	Method-of-treatment patent
Current status	Expired
Statutory term	Approximately 20 years from the nonprovisional filing date, subject to any patent-term adjustment
Expected expiry	Approximately June 30, 2020

The provisional priority date did not ordinarily determine the patent term. The relevant baseline for a patent filed in 2000 was the 20-year term from the nonprovisional filing date under 35 U.S.C. § 154. The patent is therefore no longer an enforceable barrier to generic or competing clinical use.

The patent’s expiration does not eliminate regulatory requirements for a competing product. A competing botulinum toxin still requires FDA approval or licensure, manufacturing comparability, potency characterization, sterility controls and clinical support.

How broad are the claims of US Patent 6,974,578?

The claims are broad in their therapeutic target but narrower in their practical operation than the wording initially suggests.

Claim 1: broad sweat-reduction method

Claim 1 covers administering an effective amount of botulinum toxin to reduce sweat secretion. It does not limit:

The injection site;
The dose;
The botulinum toxin serotype;
The type of sweat gland;
The anatomical location;
The formulation;
The treatment schedule; or
Whether the condition is primary or secondary hyperhidrosis.

The claim’s breadth creates several interpretive issues. “Effective amount” is a functional limitation. It requires evidence that the administered amount reduced secretion, but it does not specify a numerical dose. “Secretion” is also broad, although the claim then limits the secretion to sweat.

Claim 2: cholinergic secretion

Claim 2 narrows claim 1 to a cholinergically influenced secretion. Eccrine sweat glands are predominantly controlled by sympathetic postganglionic cholinergic nerves, unlike most sympathetic postganglionic pathways, which are adrenergic. That limitation links the patent to the physiology of eccrine sweating.

The limitation is useful for distinguishing eccrine hyperhidrosis from other secretory disorders. It is less valuable as a practical patent boundary because conventional focal hyperhidrosis treatment generally targets eccrine sweat glands.

Claims 3 and 4: type A toxin

Claims 3 and 4 focus on botulinum toxin type A. Claim 4 is a commercially direct claim for treating cholinergic sweating in a human with botulinum toxin type A.

The claim does not require the product to be Botox by name. A different onabotulinumtoxinA formulation, or potentially another botulinum toxin type A product, could fall within the claim if the other limitations were met. Because the patent has expired, that product-by-product distinction now has historical rather than current enforcement significance.

Claims 5-10: gland-directed treatment

Claims 5 through 10 shift from treating a patient’s secretion to treating a gland. Claim 9 expressly covers injection into the sweat gland or local area of the gland.

This language could create an infringement dispute over whether injection into skin overlying a sweat-gland field is “into the local area” of the gland. A commercial hyperhidrosis injection usually deposits toxin intradermally or superficially in a grid pattern rather than directly into individually identified glands. The claim therefore raises a fact-intensive question about injection depth, location and the meaning of “local area.”

Claim 10 is the most clinically recognizable narrow claim. It requires excessive secretion, a cholinergic nervous system-influenced sweat gland, a human patient, botulinum toxin type A and injection into the gland or local area.

Claims 11 and 12: all seven classical serotypes

Claims 11 and 12 cover botulinum toxin types A through G. The Markush language attempts to extend the claims beyond type A products. Its breadth may create written-description and enablement issues because the clinical evidence and commercial development historically centered on type A, particularly Botox.

A patent claim may cover a genus even when examples do not individually demonstrate every species. The question is whether the specification reasonably supports the full claimed genus and enables its scope. The inclusion of types B through G would have been more vulnerable if the specification lacked adequate teaching regarding potency, dosing, formulation, immunogenicity, safety and clinical performance for those serotypes.

What are the principal validity weaknesses?

The patent’s strongest feature was the clinical specificity of reducing excessive sweating. Its principal weaknesses were the breadth of the toxin genus and the reliance on a known mechanism.

Obviousness risk

A challenger could argue that the claims were obvious from the combination of:

Botulinum toxin’s known inhibition of acetylcholine release;
The cholinergic innervation of eccrine sweat glands;
Prior botulinum toxin use in localized neuromuscular disorders;
Experimental or clinical evidence of reduced secretory activity; and
The known therapeutic objective of reducing excessive sweating.

The patent’s counterargument would focus on the clinical uncertainty involved in translating neuromuscular chemodenervation into reliable, durable and safe suppression of sweating. The treatment also required identifying appropriate injection fields, dosing and retreatment intervals.

The outcome would likely depend on the specific prior art date, whether it disclosed sweat reduction rather than merely acetylcholine inhibition, and whether a skilled person had a reasonable expectation of success.

Written-description risk

Claims 11 and 12 cover seven serotypes, but commercial evidence largely concerned type A. A challenger could contend that the specification did not demonstrate possession of the entire A-G genus.

Claims 1 and 5 also use broad functional language covering sweat secretion generally and sweat glands generally. A written-description challenge would ask whether the disclosure supported treatment of all claimed anatomical sites, gland types, patient populations and toxin formulations.

Enablement risk

Enablement questions would focus on whether the patent taught the skilled person to practice the full scope without undue experimentation. Relevant variables include:

Serotype;
Potency units;
Dilution;
Injection volume;
Injection depth;
Number of injection sites;
Treatment area;
Duration of effect;
Risk of muscle weakness;
Risk of compensatory sweating; and
Retreatment timing.

These issues were more significant for claims 11 and 12 than for claim 4, which is concentrated on human treatment with type A toxin.

Indefiniteness and construction risk

Terms such as “effective amount,” “therapeutically effective amount,” “excessively secreting,” “local area” and “cholinergically influenced” require interpretation. They are not automatically indefinite, but their application depends on the specification and ordinary clinical meaning.

For an infringement action, the patent owner would need to show more than use of botulinum toxin in a patient with sweating. The owner would need to prove each claim limitation, including the purpose or result of reducing sweat secretion where that limitation is treated as limiting, and the required injection location for claims 9 and 10.

What FDA products and indications relate to the patent?

Botox, onabotulinumtoxinA, received FDA approval for severe primary axillary hyperhidrosis inadequately managed with topical agents. The indication is narrower than the full patent claim set because it focuses on severe primary axillary disease rather than all sweat secretion or all sweat glands. FDA labeling describes intradermal administration to the axilla and provides a defined dose and injection approach. (FDA, 2024a)

Product	Active ingredient	FDA hyperhidrosis status	Relationship to US 6,974,578
Botox	OnabotulinumtoxinA	Approved for severe primary axillary hyperhidrosis	Direct commercial product relevance
Dysport	AbobotulinumtoxinA	Not approved by FDA for hyperhidrosis	Potentially within historical serotype A claim scope, but no current patent barrier
Xeomin	IncobotulinumtoxinA	Not approved by FDA for hyperhidrosis	Same patent-era method-of-use issue
Myobloc	RimabotulinumtoxinB	Approved for cervical dystonia and sialorrhea, not hyperhidrosis	Potential historical relevance under type B claims
Daxxify	DaxibotulinumtoxinA-lanm	Approved for selected aesthetic and therapeutic indications, not hyperhidrosis	Possible future competitive product, subject to FDA approval
Qbrexza	Glycopyrronium tosylate	Topical axillary hyperhidrosis treatment	Non-toxin competitor
Sofdra	Sofpironium	FDA-approved topical treatment for primary axillary hyperhidrosis	Non-toxin competitor

FDA approval of Botox for axillary hyperhidrosis did not create patent rights. It established regulatory approval for a specific indication. The patent provided method-of-use exclusivity until expiry.

What is the Orange Book and Purple Book status?

Botox is regulated as a biological product under a biologics license application rather than as a conventional small-molecule drug approved through an NDA-and-ANDA framework. The ordinary generic-substitution model does not apply.

The principal regulatory pathways are:

A biosimilar or interchangeable biosimilar application under the Biologics Price Competition and Innovation Act;
A full BLA for a competing botulinum toxin; or
A supplemental application by the existing sponsor.

The Purple Book is the relevant FDA reference for licensed biological products and biosimilar competition. FDA patent-listing procedures for biologics also differ from the traditional Orange Book system used for small-molecule products. (FDA, 2024b)

No unexpired patent claim in US 6,974,578 currently blocks a biosimilar, follow-on botulinum toxin, or off-label use. A sponsor still must address other patents, FDA exclusivity, manufacturing differences and clinical data requirements.

When did US Patent 6,974,578 lose exclusivity?

The patent lost enforceable patent exclusivity around June 30, 2020, based on the 20-year term calculated from the June 30, 2000 nonprovisional filing date. Any patent-term adjustment could alter the precise date, but the patent is no longer an active exclusivity right.

The relevant timeline is:

Date	Event
June 30, 1999	Earliest claimed priority
June 30, 2000	Nonprovisional filing
2004	FDA approval of Botox for severe primary axillary hyperhidrosis
December 13, 2005	US 6,974,578 issued
Approximately June 30, 2020	20-year patent term ended
2024	FDA approved Sofdra for primary axillary hyperhidrosis

The patent therefore did not provide current protection against a Paragraph IV challenge. A Paragraph IV certification would have been relevant before expiry if the patent had been listed against an applicable FDA product and an ANDA filer sought approval before the listed patent expired. For Botox, however, the principal competitive pathway is biologic competition rather than a conventional ANDA.

Which companies are challenging the Botox hyperhidrosis franchise?

The competitive threat is not confined to patent challengers. It includes alternative toxins, topical anticholinergics, energy-based procedures and surgical interventions.

Botulinum toxin competitors

Dysport, Xeomin, Myobloc and Daxxify compete in adjacent botulinum toxin markets. Their principal barriers are regulatory approval, clinical differentiation, physician familiarity, manufacturing capacity and reimbursement, not US 6,974,578.

A company seeking a hyperhidrosis indication would need to establish an acceptable benefit-risk profile and an indication-specific clinical data package. The expired patent reduces legal risk but does not eliminate FDA development risk.

Topical and non-toxin competitors

Qbrexza and Sofdra compete directly in axillary hyperhidrosis without using botulinum toxin. Their value proposition is repeat topical treatment rather than injections, while their disadvantages can include local anticholinergic effects, application burden and potentially lower suitability for severe or multifocal disease.

Other treatment options include oral anticholinergics, iontophoresis, microwave procedures and sympathectomy. These alternatives reduce the commercial importance of a toxin-only patent estate.

What manufacturing and formulation patents could still block competition?

US 6,974,578 is a method-of-treatment patent. It does not, on the face of the asserted claims, claim:

A specific botulinum toxin manufacturing process;
A particular excipient system;
A lyophilized or vacuum-dried formulation;
A reconstitution method;
A stabilizing protein;
A defined potency assay;
A delivery device;
A sustained-release formulation; or
A proprietary manufacturing cell line.

A competitor could avoid this patent by developing a different formulation or manufacturing process, but such design-around would not have been necessary after expiry. The more relevant current barriers may include process patents, formulation patents, delivery-device rights, trade secrets and know-how held by individual toxin manufacturers.

Botulinum toxin manufacturing is difficult to replicate because potency consistency, complex biological purification, sterility, aggregation control, protein stability and lot-release testing require specialized facilities. Those manufacturing barriers can sustain commercial differentiation even after method-of-use patents expire.

How strong was the patent estate compared with competing drug patents?

Factor	US 6,974,578 assessment
Claim breadth	Broad at the treatment-concept level
Claim clarity	Moderate; several functional terms require construction
Clinical relevance	High for injected type A treatment of focal hyperhidrosis
Serotype coverage	Broad, but claims 11-12 carry enablement and written-description risk
Formulation protection	Minimal or absent in the listed claims
Manufacturing protection	Minimal or absent in the listed claims
Geographic coverage	US only
Current enforceability	None because the patent has expired
Regulatory leverage	Historically meaningful for Botox; limited today
Design-around options	Historically available through non-toxin therapies, different indications and potentially different treatment approaches
Biosimilar relevance	No current blocking effect

The patent estate was strongest as an early indication patent tied to Botox’s FDA-approved axillary hyperhidrosis use. It was weaker as a durable platform estate because the claims did not, in the supplied claim set, protect the product’s composition, manufacturing process or delivery technology.

What patent litigation and settlement risks remain?

There is no continuing enforcement risk from US 6,974,578 itself after expiration. Any historical litigation involving Botox, botulinum toxin products or hyperhidrosis treatment would need to be separated from disputes concerning other Allergan patents, trademarks, formulations, manufacturing processes or unrelated indications.

A historical defendant could have challenged the patent through:

Invalidity defenses under 35 U.S.C. §§ 102, 103, 112 and 101;
Noninfringement based on a non-sweat indication;
Noninfringement based on a non-cholinergic target;
A dispute over “local area” or injection location;
A dispute over whether the accused product reduced sweat as claimed; or
A settlement providing a license or delayed entry.

Those theories have limited present value because patent expiry removes the forward-looking injunction and royalty leverage. They remain relevant for historical damages, prior settlement interpretation and freedom-to-operate opinions concerning continuation patents.

What generic or biosimilar launch risks exist?

For US 6,974,578, patent-based launch risk is effectively zero because the patent has expired. The remaining launch risks are regulatory and operational:

FDA approval or licensure for the proposed hyperhidrosis indication;
Demonstration of comparable clinical performance;
Potency and assay comparability;
Immunogenicity control;
Manufacturing scale and batch consistency;
Physician adoption;
Reimbursement and coding;
Distribution and cold-chain requirements; and
Freedom to operate under other unexpired patents.

A biosimilar applicant may not need to reproduce Botox’s exact formulation or manufacturing process. It must meet the statutory and FDA evidentiary standards for biosimilarity, including highly similar structure and no clinically meaningful differences in safety, purity and potency. (FDA, 2024c)

Key Takeaways

US 6,974,578 claimed botulinum toxin treatment of sweat secretion, particularly cholinergically influenced hyperhidrosis.
Claim 4 most directly covered Botox-type treatment of human focal hyperhidrosis with botulinum toxin type A.
Claim 10 added the commercially relevant injection-into-gland or local-area limitation.
Claims 11 and 12 extended coverage to botulinum toxin types A through G but presented greater written-description and enablement risk.
The patent’s main validity vulnerabilities were obviousness, broad functional language and support for all serotypes and sweat-gland applications.
The patent expired around June 30, 2020, eliminating current enforcement and Paragraph IV risk from this patent.
Botox’s hyperhidrosis indication remains FDA-approved, but competing botulinum toxin products generally require separate regulatory support for the indication.
Current competition includes other toxins, Qbrexza, Sofdra and procedural treatments.
Manufacturing know-how, formulation controls and biological-product regulation remain more important than this expired method patent.

FAQs

Does US Patent 6,974,578 cover Botox for facial sweating?

Historically, its broad sweat-reduction claims could have implicated treatment of facial or other focal sweating, depending on claim construction and the facts of administration. The patent is expired and cannot currently block that use.

Can a physician use Dysport or Xeomin for hyperhidrosis without infringing this patent?

Yes, US 6,974,578 is expired. Off-label use remains subject to medical judgment and applicable regulatory requirements, but this patent no longer creates an enforceable restriction.

Did the patent cover oral botulinum toxin treatment?

No practical oral treatment is implicated by the supplied claims. The claims contemplate administering botulinum toxin to a patient or sweat gland, with the specification and clinical practice centered on local administration.

Does the expired patent provide exclusivity for the Botox brand?

No. Patent expiry does not create or preserve trademark, regulatory, formulation or manufacturing exclusivity. Botox remains a brand and biologic product subject to its own regulatory and commercial rights.

Are botulinum toxin products interchangeable for hyperhidrosis?

No. Different botulinum toxin products have distinct molecular structures, potency assays, units, dosing conventions, labels and clinical evidence. Units are not automatically interchangeable across products.

References

Allergan, Inc. (2005). Treatment of hyperhidrosis with botulinum toxin (U.S. Patent No. 6,974,578). United States Patent and Trademark Office.
Food and Drug Administration. (2024a). BOTOX prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024b). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024c). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
United States Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119.
United States Patent and Trademark Office. (2024). Manual of Patent Examining Procedure, §§ 2161-2165. U.S. Department of Commerce.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	9-Dec-91	6,974,578	2016-04-03
Abbvie Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	9-Dec-91	6,974,578	2016-04-03
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9517904	⤷ Start Trial
United States of America	2001018415	⤷ Start Trial
United States of America	2001041181	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 6,974,578

Summary for Patent: 6,974,578